This correlated with a retrospective study on patients with psoriasis treated with a TNF-α inhibitor or ustekinumab, that demonstrated longer drug survival and the lowest proportion of loss of efficacy for ustekinumab compared with the TNF-α inhibitors. This evidence concerns the gene TNF and psoriasis.